PURPOSE: Recurrence is the major factor influencing the clinical outcome of meningioma patients although the exact relationship between primary and recurrent tumors still needs to be clarified. The aim of the present study is to analyze the cytogenetic relationship between primary and subsequent recurrent meningiomas developed within the same individual. EXPERIMENTAL DESIGN: Multicolor interphase fluorescence in situ hybridization was done for the identification of numerical abnormalities of 12 chromosomes in single-cell suspensions from 59 tumor samples corresponding to 25 recurrent meningioma patients. In 47 of these tumors, the distribution of different tumor cell clones was also analyzed in paraffin-embedded tissue sections. In parallel, 132 nonrecurrent cases were also studied. RESULTS: Most recurrent meningiomas showed complex cytogenetic aberrations associated with two or more tumor cell clones in the first tumor analyzed. Interestingly, in most individuals (74%), exactly the same tumor cell clones identified in the initial lesion were also detected in the subsequent recurrent tumor samples. In the recurrent tumor samples of the remaining cases (26%), we observed tumor cell clones related to those detected in the initial lesion but which had acquired one or more additional chromosome aberrations associated with either the emergence of new clones with more complex karyotypes or the disappearance of the most representative clones from the primary lesions. Multivariate analysis of prognostic factors showed that the Maillo et al. prognostic score, based on age of patient, tumor grade, and monosomy 14, together with tumor size was the best combination of independent variables for predicting tumor recurrence at diagnosis. CONCLUSION: Overall, our results indicate that the development of recurrent meningiomas after complete tumor resection is usually due to regrowth of the primary tumor and rarely to the emergence of an unrelated meningioma, underlining the need for alternative treatment strategies in cases at high risk of relapse, particularly those with a high Maillo et al. prognostic score and larger tumors.
PURPOSE: Recurrence is the major factor influencing the clinical outcome of meningiomapatients although the exact relationship between primary and recurrent tumors still needs to be clarified. The aim of the present study is to analyze the cytogenetic relationship between primary and subsequent recurrent meningiomas developed within the same individual. EXPERIMENTAL DESIGN: Multicolor interphase fluorescence in situ hybridization was done for the identification of numerical abnormalities of 12 chromosomes in single-cell suspensions from 59 tumor samples corresponding to 25 recurrent meningiomapatients. In 47 of these tumors, the distribution of different tumor cell clones was also analyzed in paraffin-embedded tissue sections. In parallel, 132 nonrecurrent cases were also studied. RESULTS: Most recurrent meningiomas showed complex cytogenetic aberrations associated with two or more tumor cell clones in the first tumor analyzed. Interestingly, in most individuals (74%), exactly the same tumor cell clones identified in the initial lesion were also detected in the subsequent recurrent tumor samples. In the recurrent tumor samples of the remaining cases (26%), we observed tumor cell clones related to those detected in the initial lesion but which had acquired one or more additional chromosome aberrations associated with either the emergence of new clones with more complex karyotypes or the disappearance of the most representative clones from the primary lesions. Multivariate analysis of prognostic factors showed that the Maillo et al. prognostic score, based on age of patient, tumor grade, and monosomy 14, together with tumor size was the best combination of independent variables for predicting tumor recurrence at diagnosis. CONCLUSION: Overall, our results indicate that the development of recurrent meningiomas after complete tumor resection is usually due to regrowth of the primary tumor and rarely to the emergence of an unrelated meningioma, underlining the need for alternative treatment strategies in cases at high risk of relapse, particularly those with a high Maillo et al. prognostic score and larger tumors.
Authors: Angel Maillo; Alberto Orfao; Ana B Espinosa; José María Sayagués; Marta Merino; Pablo Sousa; Monica Lara; María Dolores Tabernero Journal: Neuro Oncol Date: 2007-08-17 Impact factor: 12.300
Authors: Patrícia Henriques Domingues; Pablo Sousa; Álvaro Otero; Jesus Maria Gonçalves; Laura Ruiz; Catarina de Oliveira; Maria Celeste Lopes; Alberto Orfao; Maria Dolores Tabernero Journal: Neuro Oncol Date: 2014-02-16 Impact factor: 12.300
Authors: María González-González; Jacinto Garcia; José A Alcazar; María L Gutiérrez; Luis M Gónzalez; Oscar Bengoechea; María M Abad; Angel Santos-Briz; Oscar Blanco; Manuela Martín; Ana Rodríguez; Manuel Fuentes; Luis Muñoz-Bellvis; Alberto Orfao; Jose M Sayagues Journal: Medicine (Baltimore) Date: 2014-11 Impact factor: 1.889
Authors: Patrícia Domingues; María González-Tablas; Álvaro Otero; Daniel Pascual; Laura Ruiz; David Miranda; Pablo Sousa; Jesús María Gonçalves; María Celeste Lopes; Alberto Orfao; María Dolores Tabernero Journal: Oncotarget Date: 2015-05-10
Authors: Patrícia Henriques Domingues; Cristina Teodósio; Álvaro Otero; Pablo Sousa; Javier Ortiz; María del Carmen García Macias; Jesús María Gonçalves; Ana Belén Nieto; María Celeste Lopes; Catarina de Oliveira; Alberto Orfao; Maria Dolores Tabernero Journal: PLoS One Date: 2013-10-01 Impact factor: 3.240